144: Filer Information

Filer CIK

0001363364

Filer CCC

XXXXXXXX

Is this a LIVE or TEST Filing?

LIVE

TEST

Submission Contact Information

Name

Phone

E-Mail Address

144: Issuer Information

Name of Issuer

BeiGene, Ltd.

SEC File Number

001-37686

Address of Issuer

94 Solaris Avenue, Camana Bay
Grand Cayman
Cayman Islands
CAYMAN ISLANDS
KY1 1108

Phone

345-949-4123

Name of Person for Whose Account the Securities are To Be Sold

Baker Brothers Life Sciences, L.P.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Affiliate

144: Securities Information

Title of the Class of Securities To Be Sold

Name and Address of the Broker

Number of Shares or Other Units To Be Sold

Aggregate Market Value

Number of Shares or Other Units Outstanding

Approximate Date of Sale

Name the Securities Exchange

American Depositary Shares

J.P. Morgan
Securities LLC
383 Madison Avenue
New York � NY � 10179

950907

178074395.02

66842970

12/09/2024

NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class

Date you Acquired

Nature of Acquisition Transaction

Name of Person from Whom Acquired

Is this a Gift?

Date Donor Acquired

Amount of Securities Acquired

Date of Payment

Nature of Payment *

American Depositary Shares

08/02/2018

See Remark 2

Underwriter

402453

09/05/2018

Cash

American Depositary Shares

01/18/2018

See Remark 3

Underwriter

548454

01/22/2018

Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

(1) Baker Brothers Life Sciences, L.P. is affiliated with 667, L.P. Baker Bros. Advisors LP is the investment adviser to 667, L.P. and Baker Brothers Life Sciences, L.P. 667, L.P. is filing separately for the sale of 86,110 American Depositary Shares ("ADS") of BeiGene, Ltd (the "Issuer"), which along with the reported sales in this form by Baker Brothers Life Sciences, L.P. totals 1,037,017 ADS. Each ADS represents 13 Ordinary Shares of the Issuer. The outstanding shares number noted above represents outstanding ADS. All amounts above are expressed in ADS. (2) Purchase of Ordinary Shares in Issuer's HKEX IPO later converted to ADS. (3) Purchase of ADS in underwritten public offering.

Date of Notice

12/09/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

By: BAKER BROS. ADVISORS LP, mgmt company and IA to Baker Brothers Life Sciences, L.P., /s/ Scott L. Lessing, President

144: Filer Information

Submission Contact Information

144: Issuer Information

144: Securities Information

144: Securities To Be Sold

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

SEC Form 144 filed by BeiGene Ltd.